Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neogenomics Inc 9490 NEOGENOMICS WAY FORT MYERS FL 33912 USA

www.neogenomics.com Employees: 2,100 P: 239-768-0600 F: 239-690-4237

Description:

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.

Key Statistics

Overview:

Market Capitalization, $K 1,794,212
Enterprise Value, $K 1,451,722
Shares Outstanding, K 128,158
Annual Sales, $ 591,640 K
Annual Net Income, $ -87,970 K
Last Quarter Sales, $ 164,500 K
Last Quarter Net Income, $ -18,640 K
EBIT, $ -95,280 K
EBITDA, $ -19,820 K
60-Month Beta 1.19
% of Insider Shareholders 1.30%
% of Institutional Shareholders 98.50%
Float, K 126,492
% Float 98.70%
Short Volume Ratio 0.71

Growth:

1-Year Return 1.67%
3-Year Return -66.17%
5-Year Return -38.30%
5-Year Revenue Growth 113.79%
5-Year Earnings Growth -338.46%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.03 on 07/29/24
Next Earnings Date 11/05/24 [BMO]
Earnings Per Share ttm -0.20
EPS Growth vs. Prev Qtr 50.00%
EPS Growth vs. Prev Year 55.56%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NEO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -2.72%
Return-on-Assets % -1.53%
Profit Margin % -14.87%
Debt/Equity 0.22
Price/Sales 2.94
Price/Cash Flow 48.14
Price/Book 1.90
Book Value/Share 7.15
Interest Coverage -13.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar